Wednesday, March 12, 2025 PR17 trial publication: Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance Patients who inherited the adrenal-permissive HSD3B1 allele had more favorable 5-year clinical progression-free survival and OS when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen compared with their counterparts who did not have adrenal-permissive HSD3B1 inheritance. HSD3B1 was also associated with OS after accounting for known clinical variables. Patients with both genotypes benefited from early enzalutamide. Sharifi N, Diaz R, Lin H-M, Roberts E, Horvath LG, Martin A, Stockler MR, Yip S, Subhash VV, Portman N, Davis ID, Sweeney CJ. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. The Journal of Clinical Investigation 134: e183583. 2024. https://doi.org/10.1172/JCI183583 MA5 trial publication: Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit Assessment of the tumor-immune microenvironmentused as a prognostic tool for improved survival and as a predictive biomarker for treatment benefit, particularly from immune-modulating treatments including cytotoxic chemotherapy. Using digital spatial profiling (DSP), researchers studied the tumor-immune microenvironment of 522 breast cancer cases by quantifying 35 immune biomarkers on tissue microarrays from the MA.5 phase III clinical trial. Shenasa E, He Y, Wang Z, Tu D, Gao D, Kos Z, Thornton S, Nielsen TO. Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit. Modern Pathology 38: 100718. 2025.https://doi.org/10.1016/j.modpat.2025.100718
